Table 1 Clinicopathological characteristics of all PTLD patients

Age at transplantation in years

Median: 12.7 (0.4–65.4); mean: 22.3

Time to diagnosis after transplantation in years

Median: 2.1 (0.3–19); mean: 3.8

Age at PTLD diagnosis in years

Median: 15.7 (0.8–70.8); mean: 26.1

Age > 60 years at PTLD diagnosis

n = 4 (11.1 %)

Age < 10 years at PTLD diagnosis

n = 14 (38.9 %)

Age < 5 years at PTLD diagnosis

n = 11 (30.6 %)

Late PTLD (>365 days after Tx)

n = 24 (66.7 %)

Very early PLTD (<183 days after Tx)

n = 4 (11.1 %)

Ciclosporine at PTLD diagnosis

n = 15 (41.7 %)

Tacrolimus at PTLD diagnosis

n = 16 (44.4 %)

CNI-free immunosuppression at PTLD diagnosis

n = 5 (13.9 %)

Mycophenolat at PTLD diagnosis

n = 19 (52.8 %)

Steroids at PTLD diagnosis

n = 29 (80.6 %)

Steroid-free immunosuppression at PTLD diagnosis

n = 7 (19.4 %)

mTOR inhibitors at PTLD diagnosis

n = 1 (2.8 %)

Number of graft rejections prior to PTLD diagnosis

Median: 0 (0–2); mean: 0.44

Number of graft rejections after PTLD diagnosis

Median: 0 (0–1); mean: 0.25

Polymorphic PTLD

n = 5 (13.9 %)

Monomorphic PTLD

n = 28 (77.8 %)

Pure B cell neoplasm

n = 29 (80.6 %)

Diffuse large B cell neoplasm

n = 20 (55.6 %)

CD20 expression in tumor

n = 32 (88.9 %)

EBV latent membrane protein or EBV-encoded RNA in tumor cells

n = 26 (100.0 %^a, 10 cases missing data)

Detection of monoclonal disease

n = 9 (52.9 %^a, 19 cases missing data)

Extranodal disease

n = 24 (66.7 %)

Graft organ involvement

n = 4 (11.1 %)

CNS involvement

n = 7 (19.4 %)

Primary CNS lymphoma

n = 4 (11.1 %)

Bone marrow involvement

n = 6 (16.7 %)

Gastro-intestinal involvement

n = 14 (38.9 %)

Lung involvement

n = 3 (8.3 %)

Skin involvement

n = 0 (0.0 %)

Number of sites involved

Median: 2 (1–6); mean: 2.5

Stage IV disease

n = 25 (69.4 %)

B-symptoms at PTLD diagnosis

n = 4 (11.1 %)

Lactate dehydrogenase elevated at PTLD diagnosis

n = 23 (71.9 %^a, 4 cases missing data)

Hypoalbuminemia at PTLD diagnosis

n = 17 (65.4 %^a, 10 cases missing data)

EBV IgG at Tx

n = 14 (45.2 %^a, 5 cases missing data)

EBV IgM at Tx

n = 1 (3.3 %^a, 6 cases missing data)

EBV serology or DNA positive at PTLD diagnosis

n = 31 (100.0 %^a, 5 cases missing data)

EBV DNA at PTLD diagnosis

n = 29 (96.7 %^a, 6 cases missing data)

EBV IgG at PTLD diagnosis

n = 21 (77.8 %^a, 9 cases missing data)

CMV IgG at Tx

n = 12 (35.3 %^a, 2 cases missing data)

CMV IgM at Tx

n = 3 (9.7 %^a, 5 cases missing data)

CMV pp65 at Tx

n = 1 (3.8 %^a, 10 cases missing data)

CMV serology or DNA positive at PTLD diagnosis

n = 23 (100 %^a, 13 cases missing data)

CMV pp65 at PTLD diagnosis

n = 1 (4.2 %^a, 12 cases missing data)

CMV DNA at PTLD diagnosis

n = 4 (22.2 %^a, 18 cases missing data)

CMV IgM at PTLD diagnosis

n = 7 (30.4 %^a, 13 cases missing data)

CMV IgG at PTLD diagnosis

n = 21 (77.8 %^a, 9 cases missing data)